These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 9123821)

  • 41. Novel DNA-launched Venezuelan equine encephalitis virus vaccine with rearranged genome.
    Tretyakova I; Tibbens A; Jokinen JD; Johnson DM; Lukashevich IS; Pushko P
    Vaccine; 2019 May; 37(25):3317-3325. PubMed ID: 31072736
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Limited potential for mosquito transmission of genetically engineered, live-attenuated Venezuelan equine encephalitis virus vaccine candidates.
    Turell MJ; Ludwig GV; Kondig J; Smith JF
    Am J Trop Med Hyg; 1999 Jun; 60(6):1041-4. PubMed ID: 10403340
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Protective efficacies of live attenuated and formaldehyde-inactivated Venezuelan equine encephalitis virus vaccines against aerosol challenge in hamsters.
    Jahrling PB; Stephenson EH
    J Clin Microbiol; 1984 Mar; 19(3):429-31. PubMed ID: 6715512
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of trivalent inactivated encephalomyelitis virus vaccine in horses.
    Barber TL; Walton TE; Lewis KJ
    Am J Vet Res; 1978 Apr; 39(4):621-5. PubMed ID: 646197
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Virulent and attenuated mutant Venezuelan equine encephalitis virus show marked differences in replication in infection in murine macrophages.
    Grieder FB; Nguyen HT
    Microb Pathog; 1996 Aug; 21(2):85-95. PubMed ID: 8844652
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mechanism of neuroinvasion of Venezuelan equine encephalitis virus in the mouse.
    Charles PC; Walters E; Margolis F; Johnston RE
    Virology; 1995 Apr; 208(2):662-71. PubMed ID: 7747437
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Melatonin treatment enhances the efficiency of mice immunization with Venezuelan equine encephalomyelitis virus TC-83.
    Negrette B; Bonilla E; Valero N; Pons H; Garcia Tamayo J; Chacín-Bonilla L; Medina-Leendertz S; Añez F
    Neurochem Res; 2001 Jul; 26(7):767-70. PubMed ID: 11565607
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Venezuelan equine encephalitis virus complex-specific monoclonal antibody provides broad protection, in murine models, against airborne challenge with viruses from serogroups I, II and III.
    Phillpotts RJ
    Virus Res; 2006 Sep; 120(1-2):107-12. PubMed ID: 16621103
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of neurovirulence and biodistribution of Venezuelan equine encephalitis replicon particles expressing herpes simplex virus type 2 glycoprotein D.
    Kowalski J; Adkins K; Gangolli S; Ren J; Arendt H; DeStefano J; Obregon J; Tummolo D; Natuk RJ; Brown TP; Parks CL; Udem SA; Long D
    Vaccine; 2007 Mar; 25(12):2296-305. PubMed ID: 17239997
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pseudotyped viruses permit rapid detection of neutralizing antibodies in human and equine serum against Venezuelan equine encephalitis virus.
    Kolokoltsov AA; Wang E; Colpitts TM; Weaver SC; Davey RA
    Am J Trop Med Hyg; 2006 Oct; 75(4):702-9. PubMed ID: 17038698
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Onset and duration of protective immunity to IA/IB and IE strains of Venezuelan equine encephalitis virus in vaccinated mice.
    Hart MK; Lind C; Bakken R; Robertson M; Tammariello R; Ludwig GV
    Vaccine; 2001 Nov; 20(3-4):616-22. PubMed ID: 11672929
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development of a Broadly Accessible Venezuelan Equine Encephalitis Virus Replicon Particle Vaccine Platform.
    Agnihothram S; Menachery VD; Yount BL; Lindesmith LC; Scobey T; Whitmore A; Schäfer A; Heise MT; Baric RS
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29540599
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genetically engineered, live attenuated vaccines for Venezuelan equine encephalitis: testing in animal models.
    Pratt WD; Davis NL; Johnston RE; Smith JF
    Vaccine; 2003 Sep; 21(25-26):3854-62. PubMed ID: 12922119
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Self-Amplifying RNA Vaccines for Venezuelan Equine Encephalitis Virus Induce Robust Protective Immunogenicity in Mice.
    Samsa MM; Dupuy LC; Beard CW; Six CM; Schmaljohn CS; Mason PW; Geall AJ; Ulmer JB; Yu D
    Mol Ther; 2019 Apr; 27(4):850-865. PubMed ID: 30770173
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vaccination of macaques with SIV immunogens delivered by Venezuelan equine encephalitis virus replicon particle vectors followed by a mucosal challenge with SIVsmE660.
    Johnston RE; Johnson PR; Connell MJ; Montefiori DC; West A; Collier ML; Cecil C; Swanstrom R; Frelinger JA; Davis NL
    Vaccine; 2005 Oct; 23(42):4969-79. PubMed ID: 16005121
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Novel vaccine against Venezuelan equine encephalitis combines advantages of DNA immunization and a live attenuated vaccine.
    Tretyakova I; Lukashevich IS; Glass P; Wang E; Weaver S; Pushko P
    Vaccine; 2013 Feb; 31(7):1019-25. PubMed ID: 23287629
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Influence of mucosal and parenteral immunization with a replication-defective mutant of HSV-2 on immune responses and protection from genital challenge.
    Morrison LA; Da Costa XJ; Knipe DM
    Virology; 1998 Mar; 243(1):178-87. PubMed ID: 9527927
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Human transcriptome response to immunization with live-attenuated Venezuelan equine encephalitis virus vaccine (TC-83): Analysis of whole blood.
    Erwin-Cohen RA; Porter AI; Pittman PR; Rossi CA; DaSilva L
    Hum Vaccin Immunother; 2017 Jan; 13(1):169-179. PubMed ID: 27870591
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Venezuelan equine encephalomyelitis virus: concentration, partial purification, inactivation and immunogenicity.
    Foster NM; Barber TL; Walton TE
    Comp Immunol Microbiol Infect Dis; 1983; 6(1):31-7. PubMed ID: 6825417
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice.
    Revaz V; Benyacoub J; Kast WM; Schiller JT; De Grandi P; Nardelli-Haefliger D
    Virology; 2001 Jan; 279(1):354-60. PubMed ID: 11145916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.